Bambusa Therapeutics – a biotechnology company focused on developing bispecific antibodies for treating immunological and inflammatory (I&I) disorders – announced the closing of its Series Seed financing round at $15 million.
Bambusa Therapeutics was launched by a team of industry experts and scientific innovators united by a vision to transform the treatment landscape for I&I diseases. And the company utilizes validated targets to create bispecific antibody therapeutics through antibody engineering, to achieve comprehensive disease profiles for multiple indications.
This funding round was co-led by BVF Partners L.P. and Dawn Biopharmaa platform controlled by KKR, with Salvia GmbH and INCE Capital participation. And the funding will be used to accelerate the development of Bambusa Therapeutics Inc.’s promising pipeline of bispecific antibodies to Phase I clinical studies.
KEY QUOTES:
“We founded Bambusa Therapeutics with a belief that the I&I field is long overdue for innovative approaches and transformative therapeutics. Since our inception, we have built a diverse portfolio of molecules and is uniquely positioned to make significant contributions to patients suffering from debilitating and chronic inflammatory conditions.”
– Dr. Shanshan Xu, CEO and Co-Founder of Bambusa Therapeutics
“We are thrilled to have the support of such distinguished investors who share our vision. This funding will allow us to strengthen the team to advance our lead candidates through preclinical development and position us for success in clinical studies.”
– Helmut Jeggle, Managing Director of Salvia GmbH and Co-Founder of Bambusa Therapeutics
